title: Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans.
abstract: Attenuated live oral typhoid vaccine candidate CVD 909 constitutively expresses Salmonella Typhi capsular polysaccharide antigen (Vi). A randomized, double-blind, heterologous prime-boost clinical study was conducted to determine whether immunity to licensed parenteral Vi vaccine could be enhanced by priming with CVD 909. Priming with CVD 909 elicited higher and persistent, albeit not significant, anti-Vi IgG and IgA following immunization with Vi, than placebo-primed recipients. Vi-specific IgA B memory (B(M)) cells were significantly increased in CVD 909-primed subjects. S. Typhi-specific LPS and flagella IgA B(M) cells were observed in subjects immunized with CVD 909 or with the licensed Vi-negative oral typhoid vaccine Ty21a. CVD 909-induced B(M) cells exhibited a classical B(M) phenotype (i.e., CD3(-)CD19(+)IgD(-)CD27(+)). This is the first demonstration of classical B(M) cells specific for bacterial polysaccharide or protein antigens following typhoid immunization. The persistent IgA B(M) responses demonstrate the capacity of oral typhoid vaccines to prime mucosally relevant immune memory.
authors.affiliation: Center for Vaccine Development, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA.
authors.forename: Rezwanul
authors.initials: R
authors.lastname: Wahid
authors.forename: Marcela F
authors.initials: MF
authors.lastname: Pasetti
authors.forename: Milton
authors.initials: M
authors.lastname: Maciel
authors.forename: Jakub K
authors.initials: JK
authors.lastname: Simon
authors.forename: Carol O
authors.initials: CO
authors.lastname: Tacket
authors.forename: Myron M
authors.initials: MM
authors.lastname: Levine
authors.forename: Marcelo B
authors.initials: MB
authors.lastname: Sztein
mesh_terms: D000293:Adolescent; D000328:Adult; D000942:Antigens, Bacterial / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology*; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology*; D007072:Immunoglobulin D / Q000276:immunology*; D007074:Immunoglobulin G / Q000276:immunology*; D007156:Immunologic Memory; D008297:Male; D008875:Middle Aged; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage / Q000276:immunology*; D022562:Salmonella Vaccines / Q000008:administration & dosage / Q000276:immunology*; D012485:Salmonella typhi / Q000276:immunology*; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000276:immunology*; D014435:Typhoid Fever / Q000276:immunology / Q000517:prevention & control; D014436:Typhoid-Paratyphoid Vaccines / Q000008:administration & dosage / Q000276:immunology; D055815:Young Adult
chemical_list: D000942:Antigens, Bacterial; D007070:Immunoglobulin A; D007072:Immunoglobulin D; D007074:Immunoglobulin G; D011135:Polysaccharides, Bacterial; D022562:Salmonella Vaccines; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7; C072772:Ty21a typhoid vaccine; D014436:Typhoid-Paratyphoid Vaccines; C054154:capsular polysaccharide, Salmonella